TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.

Fountzilas, George; Giannoulatou, Eleni; Alexopoulou, Zoi; Zagouri, Flora; Timotheadou, Eleni; Papadopoulou, Kyriaki; Lakis, Sotiris; Bobos, Mattheos; Poulios, Christos; Sotiropoulou, Maria; Lyberopoulou, Aggeliki; Gogas, Helen; Pentheroudakis, George; Pectasides, Dimitrios; Koutras, Angelos; Christodoulou, Christos; Papandreou, Christos; Samantas, Epaminontas; Papakostas, Pavlos; Kosmidis, Paris; Bafaloukos, Dimitrios; Karanikiotis, Charisios; Dimopoulos, Meletios-Athanassios; Kotoula, Vassiliki

Fountzilas, George; Giannoulatou, Eleni; Alexopoulou, Zoi; Zagouri, Flora; Timotheadou, Eleni; Papadopoulou, Kyriaki; Lakis, Sotiris; Bobos, Mattheos; Poulios, Christos; Sotiropoulou, Maria; Lyberopoulou, Aggeliki; Gogas, Helen; Pentheroudakis, George; Pectasides, Dimitrios; Koutras, Angelos; Christodoulou, Christos; Papandreou, Christos; Samantas, Epaminontas; Papakostas, Pavlos; Kosmidis, Paris; Bafaloukos, Dimitrios; Karanikiotis, Charisios; Dimopoulos, Meletios-Athanassios; Kotoula, Vassiliki.

Afiliação

Fountzilas G; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Giannoulatou E; Aristotle University of Thessaloniki, Thessaloniki, Greece.
Alexopoulou Z; Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
Zagouri F; The University of New South Wales, NSW, Australia.
Timotheadou E; Department of Biostatistics, Health Data Specialists Ltd, Athens, Greece.
Papadopoulou K; Department of Clinical Therapeutics, "Alexandra" Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Lakis S; Department of Medical Oncology, "Papageorgiou" Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
Bobos M; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Poulios C; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Sotiropoulou M; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Lyberopoulou A; Department of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
Gogas H; Department of Pathology, "Alexandra" Hospital, Athens, Greece.
Pentheroudakis G; Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Pectasides D; First Department of Medicine, "Laiko" General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Koutras A; Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.
Christodoulou C; Oncology Section, Second Department of Internal Medicine, "Hippokration" Hospital, Athens, Greece.
Papandreou C; Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece.
Samantas E; Second Department of Medical Oncology, "Metropolitan" Hospital, Piraeus, Greece.
Papakostas P; Department of Medical Oncology, University Hospital of Larissa, University of Thessaly School of Medicine, Larissa, Greece.
Kosmidis P; Third Department of Medical Oncology, "Agii Anargiri" Cancer Hospital, Athens, Greece.
Bafaloukos D; Oncology Unit, "Hippokration" Hospital, Athens, Greece.
Karanikiotis C; Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
Dimopoulos MA; First Department of Medical Oncology, "Metropolitan" Hospital, Piraeus, Greece.
Kotoula V; Department of Medical Oncology, 424 Army General Hospital, Thessaloniki, Greece.

Oncotarget ; 7(22): 32731-53, 2016 May 31.

Article em En | MEDLINE | ID: mdl-27129168

Assuntos

Antineoplásicos Imunológicos/uso terapêutico; Biomarcadores Tumorais/genética; Análise Mutacional de DNA; Imuno-Histoquímica; Mutação; Trastuzumab/uso terapêutico; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Proteína Supressora de Tumor p53/genética; Adulto; Idoso; Idoso de 80 Anos ou mais; Biomarcadores Tumorais/análise; Quimioterapia Adjuvante; Distribuição de Qui-Quadrado; Classe I de Fosfatidilinositol 3-Quinases/análise; Classe I de Fosfatidilinositol 3-Quinases/genética; Ensaios Clínicos como Assunto; Progressão da Doença; Intervalo Livre de Doença; Feminino; Predisposição Genética para Doença; Grécia; Humanos; Estimativa de Kaplan-Meier; Pessoa de Meia-Idade; Análise Multivariada; Seleção de Pacientes; Fenótipo; Valor Preditivo dos Testes; Modelos de Riscos Proporcionais; Estudos Prospectivos; Estudos Retrospectivos; Fatores de Risco; Fatores de Tempo; Resultado do Tratamento; Neoplasias de Mama Triplo Negativas/química; Neoplasias de Mama Triplo Negativas/genética; Neoplasias de Mama Triplo Negativas/patologia; Proteína Supressora de Tumor p53/análise; Adulto Jovem

Palavras-chave

PIK3CA mutations; TP53 mutations; early breast cancer; p53 immunohistochemistry; trastuzumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Análise Mutacional de DNA / Imuno-Histoquímica / Biomarcadores Tumorais / Proteína Supressora de Tumor p53 / Neoplasias de Mama Triplo Negativas / Trastuzumab / Antineoplásicos Imunológicos / Mutação Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 País/Região como assunto: Europa Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Grécia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google